BMY - Bristol-Myers Squibb Company

NYSE - NYSE Delayed Price. Currency in USD
47.49
-0.67 (-1.39%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close48.16
Open48.15
Bid47.40 x 800
Ask47.72 x 800
Day's Range47.38 - 48.20
52 Week Range44.30 - 63.75
Volume12,968,791
Avg. Volume19,194,165
Market Cap77.535B
Beta (3Y Monthly)0.86
PE Ratio (TTM)15.78
EPS (TTM)3.01
Earnings DateApr 25, 2019
Forward Dividend & Yield1.64 (3.41%)
Ex-Dividend Date2019-01-03
1y Target Est56.70
Trade prices are not sourced from all markets
  • J&J Files Application for Darzalex Label Expansion in Europe
    Zacks13 hours ago

    J&J Files Application for Darzalex Label Expansion in Europe

    J&J (JNJ) seeks an approval for Darzalex combo pertaining to the newly diagnosed, transplant-ineligible multiple myeloma patient population in the EU.

  • GlobeNewswire16 hours ago

    Report: Developing Opportunities within Bristol-Myers Squibb, AutoNation, FirstEnergy, Charles River Laboratories International, Yum! Brands, and AGNC Investment — Future Expectations, Projections Moving into 2019

    NEW YORK, March 25, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Business Wire17 hours ago

    Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction; Company Provides Additional Investor Materials

    Bristol-Myers Squibb Company’s (BMY) Board of Directors today sent an open letter to the Company’s shareholders regarding the previously announced definitive merger agreement with Celgene Corporation (CELG). In addition to its March 19 investor presentation, the Company today also made available on Bristol-Myers Squibb’s website at www.bestofbiopharma.com and later today will file with the Securities and Exchange Commission (SEC) an investor presentation providing an overview of Bristol-Myers Squibb’s ability to derive value from Celgene’s pipeline and a Fact Sheet providing additional detail on key benefits of the transaction.

  • Is It Safe to Buy Biogen Stock Right Now?
    InvestorPlaceyesterday

    Is It Safe to Buy Biogen Stock Right Now?

    On Thursday, shares of Biogen (NASDAQ:BIIB) were hammered, falling more than 29% in just one session. Biogen stock was again under pressure on Friday, falling almost 3% on the day. The move puts the stock down massively on the week and below key support.Source: Biogen via YouTubeBut what's got BIIB stock under pressure in the first place?On Thursday morning, Biogen announced that it and development partner Eisai would terminate two stage 3 clinical trials for their Alzheimer's treatment, aducanumab. As InvestorPlace's Aaron Levitt put it (linked above): "The massive drop was truly an unsettling surprise for BIIB shareholders as the drug was seen as a multi-billion blockbuster and game-changing medication for treating the disease. It really did come out of nowhere."InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt has many investors trapped above at higher prices, with some investors wondering if now's the time to get long. Let's digest the charts here. Trading Biogen Stock Click to EnlargeDespite axing what many were hoping would be a robust treatment, Biogen's fundamentals are still intact. However, the charts are not. Above is a five-year weekly chart highlighting just how much technical damage was dealt out over the past two days. * The 10 Best ETFs to Buy in the Second Quarter It's crazy how much can change in one day. With Biogen stock, we have the stock plunging through the 10-week, 50-week and 200-week moving averages, as well as falling below key support. $250 has been long-time support, buoying BIIB stock for much of the past five years. The exception came in 2016, when Biogen stock broke below this mark for about six months.When that happened, $230 stood tall, but even that mark failed to prop up Biogen this time. What are investors going to do? A retest of the lows near $210 certainly seems to be in the cards now, but the rebound is what has me concerned. Should BIIB stock bounce, bulls need to see what role $250 plays. If this mark acts as resistance, Biogen could be a tough one to own for a while. If it gives way and the stock is able to get back above this mark, then BIIB has a chance to reclaim its prior range.Aggressive bulls could justify a new position in Biogen stock with a stop-loss near the 2016 lows. Conservative bulls may want to wait for a possible retest of those lows or at least a further decline before starting to nibble.In either case, $250 will be an important test at some point. Valuing BIIB StockDespite the technical thrashing, the fundamentals still look attractive. Revenue estimates call for just 2.2% growth this year to $13.75 billion, while earnings expectations call for 9.4% growth to $28.67 per share. That leaves Biogen stock trading at a very low valuation, at just 7.7 times this year's earnings.It would be one thing if Biogen had negative earnings and revenue expectations for this year and next year. But that's not the case, while cash flow generation remains strong. Over the past 12 months, BIIB has generated free cash flow of more than $5.3 billion. That leaves BIIB stock trading at about 8.4 times its trailing free cash flow.Guys, these aren't expensive numbers here, even with the disappointing Alzheimer's news and the lack of robust growth. That said, the discount to the stock price isn't surprising. Just look at a company like Celgene (NASDAQ:CELG), which has forecast for double-digit earnings and revenue growth this year and next year, yet trades at just 8.5 times this year's earnings. And that's with a pending buyout offer from Bristol-Myers Squibb (NYSE:BMY).I would rather be long CELG (and for that matter, I am) than Biogen stock at this point. That said, long-term investors could justify soon nibbling a position in the latter as it nears a potential capitulation low.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, he was long CELG. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio Compare Brokers The post Is It Safe to Buy Biogen Stock Right Now? appeared first on InvestorPlace.

  • Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now
    Zacks4 days ago

    Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.

  • Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market
    Zacks5 days ago

    Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market

    Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.

  • Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition
    Zacks5 days ago

    Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition

    The acquisition deal between Bristol-Myers and Celgene faces opposition from stakeholders of Bristol-Myers. The future of the deal depends on the outcome of the Special Meeting in April.

  • Barrons.com5 days ago

    Proxy Advisors Could Tilt the Scales in the Bristol-Celgene Deal. Watch for Their Calls Next Week.

    Management and shareholders at Bristol-Myers Squibb continue to spar over the firm’s proposed acquisition of Celgene. Recommendations from proxy-advisory firms will be critical to whether the deal goes ahead.

  • Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
    Zacks5 days ago

    Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

    Bristol-Myers Squibb (BMY) closed the most recent trading day at $49.21, moving -0.78% from the previous trading session.

  • Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study
    Zacks6 days ago

    Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study

    Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio and its new PARP inhibitor, Talzenna. This is the third ovarian cancer study failure in less than six months.

  • Starboard vs. Bristol-Myers Squibb: Who'll Win This Brewing Battle?
    Motley Fool6 days ago

    Starboard vs. Bristol-Myers Squibb: Who'll Win This Brewing Battle?

    An activist investor made a strong argument for walking away from Celgene, but will investors listen?

  • Analysts Have Revised BMY’s Target Price Downward in March
    Market Realist6 days ago

    Analysts Have Revised BMY’s Target Price Downward in March

    How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target priceAnalysts expect an upside potential of 13.72% for Bristol-Myers Squibb (BMY) based on the company’s closing price on

  • Barrons.com6 days ago

    Starboard Is Against the Bristol-Myers and Celgene Deal. Now It Gets Interesting.

    Less than a month before shareholders vote on Bristol-Myers Squibb’s proposed take over of Celgene, activist hedge fund Starboard Value released a presentation detailing its opposition to the deal.

  • TheStreet.com6 days ago

    Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat

    traded blows with activist investor Starboard Value LP Tuesday as the pair issued competing presentations linked to the pharmaceutical group's planned $74 billion takeover of cancer drug specialist Celgene Corp. Bristol Myers said the deal, which if first unveiled in early January, would mean give combined companies number one positions in oncology and cardiovascular drug sales, with a top five standing in immunology and inflammation and nine currency products with over $1 billion in sales. Starboard, for its part, opposes the deal, arguing Celgene is a company facing a "massive patent cliff" that will force it to replace some 60% of its revenues over the next seven years.

  • Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer
    Zacks6 days ago

    Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer

    Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

  • TheStreet.com7 days ago

    Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers

    posted a wider-than-expected fourth quarter loss but said sales nearly tripled in a growing global market for medical marijuana. Tilray said earnings for the three months ending in December were pegged at a net loss of 33 cents per share, compared to a 4 cents per share profit from the same period in 2017, a figure it put down to "operating expenses related to growth initiatives, expansion of international teams and costs related to financings and M&A activities." Group sales, however, rose more than 200% to $15.5 million, while total kilogram equivalents increased nearly three-fold to 2,053 and the average net selling price rose 5.5% to $7.52 per gram, reported TheStreet's Martin Baccardax. Elon Musk is still in hot water with the SEC about his Twitter presence.

  • Bristol-Myers Squibb and Starboard Value square off over Celgene deal
    American City Business Journals7 days ago

    Bristol-Myers Squibb and Starboard Value square off over Celgene deal

    Activist investor says Bristol-Myers' Celgene deal "is ill-advised and could destroy substantial value for shareholders"; Bristol-Myers argues the deal "is a financially and strategically compelling transaction."

  • Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?
    Zacks7 days ago

    Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?

    Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?

  • PR Newswire7 days ago

    Starboard Issues Investor Presentation Opposing Bristol-Myers Squibb's Ill-Advised Proposed Acquisition of Celgene

    Mails Definitive Proxy Materials and a BLUE Proxy Card for Shareholders to Vote AGAINST the Proposed Transaction at the Upcoming Special Meeting Believes the Proposed Merger with Celgene is Not in the ...

  • Business Wire7 days ago

    Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene

    Bristol-Myers Squibb Company (BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with its previously announced definitive merger agreement with Celgene Corporation (CELG). The investor presentation is available on the SEC’s website at www.SEC.gov and on Bristol-Myers Squibb’s website at https://www.bms.com/investors.html. The Celgene acquisition is a financially and strategically compelling transaction.

  • Reuters7 days ago

    U.S. FDA approves Roche's small cell lung cancer treatment

    Swiss drugmaker Roche Holding AG's U.S. unit Genentech said on Monday its immunotherapy Tecentriq won approval for a tough-to-treat type of lung cancer, the latest win for the drug whose sales trail medicines from Merck & Co and Bristol-Myers Squibb. The U.S. Food and Drug Administration (FDA) approved Tecentriq plus chemotherapy for untreated extensive-stage small cell lung cancer (SCLC), after a study showed patients getting the drug cocktail lived a median 12.3 months, compared to 10.3 months for those getting chemotherapy alone, Genentech said in a statement.

  • Bristol-Myers & Pfizer Release Phase IV Data on Eliquis
    Zacks7 days ago

    Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

    Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).

  • Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
    Zacks7 days ago

    Novartis' (NVS) Alcon Acquired PowerVision for $285 Million

    Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.

  • AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention
    Business Wire8 days ago

    AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention

    AUGUSTUS is the largest trial in this high-risk patient population requiring both anticoagulant and antiplatelet therapies

  • Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?
    Motley Fool10 days ago

    Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?

    This mega-merger could be on the rocks following objections by high-profile investors.